Our Input-Transform-Output (ITO) platform addresses key challenges of small & large molecule drug discovery

  • We use atomistic modeling and parallel simulations to generate billions of computational data points, which are purpose built for our SOTA AI models.

  • We design surrogate biological assays using next
    generation sequencing to generate billions of biological
    data points purpose built for training our AI models.

  • Our state-of-the-art robotics-driven lab automation facility enables us to design and scale ground truth biological assays for validating our AI designed small and large molecules, by integrating massive data, AI, and lab automation in the same closed loop.

  • We deploy a variety of SOTA model architectures for therapeutic design (LLMs, SLMs, RLHF, diffusion models, and attentive graph neural networks) customized for the small or large molecule discovery problem at hand.

  • We leverage several computational methods to drive our drug discovery ITO™ platform including MDS, QM, MM, QM/MM, FEP, and molecular docking. Our partnership with Microsoft provides unprecedented access to Azure Quantum Elements, which increases the scale, speed, and accuracy of these physics-based simulations.

  • Our platform narrows AI designed molecules based on drug likeness predictions across absorption, distribution, metabolism, excretion, and toxicity (ADMET).

  • We optimize for high synthetic yield of our AI designed small and large molecules to improve manufacturability in the next iteration.

  • We leverage our SOTA robotics-driven lab facility to design and scale wet lab ground truth biochemical, cellular, and pharmacological in vitro assays for training our AI models, and validating the small and large molecule therapeutics they design.

  • We evaluate small and large molecules in a
    variety of ADME assays to assess drug-likeness.

  • For small and large molecule candidates, we establish PK/PD relationships and validate them in vivo.

Modality Agnostic
ITO Platform

We address key challenges of small & large molecule drug discovery with our Input-Transform-Output (ITO™) platform.



Large Molecules

  • Peptides
  • Monoclonal Antibodies
  • VHHs
  • ADCs
  • Fabs
  • ...and more

Small Molecules
  • Traditional Small Molecules
  • Covalent Inhibitors
  • Protein Degraders
  • Protein Stabilizers
  • ...and more

Therapeutic Areas


  • Precision Neuroscience
  • Autoimmune & Immunology
  • Precision Oncology
  • Rare & Genetic Diseases
  • Infectious Diseases

Partnering Models


We offer a variety of engagement models.

  • Co-Discovery Partnerships
  • Co-Engineering Partnerships
  • Platform-as-a-Service
  • Asset Licensing


Our unprecedented collaboration with Microsoft will build the most powerful, fully-integrated, AI-driven drug discovery and development platform to dramatically improve pharmaceutical R&D productivity, and bring novel therapeutics to patients faster and more cost-effectively than traditional approaches.

learn more